Epidemiology of cholangiocarcinoma

F. Turati, P. Bertuccio, E. Negri, C. La Vecchia
{"title":"Epidemiology of cholangiocarcinoma","authors":"F. Turati, P. Bertuccio, E. Negri, C. La Vecchia","doi":"10.20517/2394-5079.2021.130","DOIUrl":null,"url":null,"abstract":"Aim: We aimed to analyze temporal trends in mortality from intrahepatic (ICC) and extrahepatic (ECC) cholangiocarcinoma in selected countries worldwide. Methods: Official death certification data for ICC and ECC and populations estimates for 29 countries worldwide (17 from Europe, 8 from the Americas, and 4 from Australasia) and for Hong Kong Special Administrative Region of the People’s Republic of China (SAR), from 1995 to 2018, were extracted from the World Health Organization and the Pan American Health Organization databases. Age-standardized mortality rates were computed. A joinpoint regression analysis was performed. Results: In both sexes, ICC mortality rates increased in most countries considered, including the USA, the UK, and Australia; in some countries, including Italy and France, the increasing trends leveled off over the most recent years. In men, around 2016, the highest rates (1.7-2.3/100,000) were observed in Hong Kong SAR, Portugal, France, Spain, Australia, Austria, the UK, and Canada; Latin American countries and some eastern European countries had the lowest rates (0.2-0.8/100,000). A similar pattern was observed in women, but with lower rates (from 1.7/100,000 in Hong Kong SAR to 0.14/100,000 in Argentina). ECC mortality declined in most European and Australasian countries, but it tended to increase in Americas. In both sexes, rates were below 1/100,000 around 2016, with the only exceptions being Japan (2.6/100,000 men and 1.2/100,000 women) and Hungary (1.5/100,000 men and 1.1/100,000 women). Conclusion: ICC mortality increased in most areas of the world, likely due to increased prevalence of risk factors and improved cancer recognition and classification. ECC mortality fell in most countries, largely due to the widespread use of cholecystectomy.","PeriodicalId":12959,"journal":{"name":"Hepatoma Research","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatoma Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.20517/2394-5079.2021.130","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

Aim: We aimed to analyze temporal trends in mortality from intrahepatic (ICC) and extrahepatic (ECC) cholangiocarcinoma in selected countries worldwide. Methods: Official death certification data for ICC and ECC and populations estimates for 29 countries worldwide (17 from Europe, 8 from the Americas, and 4 from Australasia) and for Hong Kong Special Administrative Region of the People’s Republic of China (SAR), from 1995 to 2018, were extracted from the World Health Organization and the Pan American Health Organization databases. Age-standardized mortality rates were computed. A joinpoint regression analysis was performed. Results: In both sexes, ICC mortality rates increased in most countries considered, including the USA, the UK, and Australia; in some countries, including Italy and France, the increasing trends leveled off over the most recent years. In men, around 2016, the highest rates (1.7-2.3/100,000) were observed in Hong Kong SAR, Portugal, France, Spain, Australia, Austria, the UK, and Canada; Latin American countries and some eastern European countries had the lowest rates (0.2-0.8/100,000). A similar pattern was observed in women, but with lower rates (from 1.7/100,000 in Hong Kong SAR to 0.14/100,000 in Argentina). ECC mortality declined in most European and Australasian countries, but it tended to increase in Americas. In both sexes, rates were below 1/100,000 around 2016, with the only exceptions being Japan (2.6/100,000 men and 1.2/100,000 women) and Hungary (1.5/100,000 men and 1.1/100,000 women). Conclusion: ICC mortality increased in most areas of the world, likely due to increased prevalence of risk factors and improved cancer recognition and classification. ECC mortality fell in most countries, largely due to the widespread use of cholecystectomy.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
胆管癌的流行病学
目的:我们旨在分析全球选定国家肝内(ICC)和肝外(ECC)胆管癌死亡率的时间趋势。方法:从世界卫生组织和泛美卫生组织数据库中提取1995年至2018年全球29个国家(欧洲17个,美洲8个,大洋洲4个)和中华人民共和国香港特别行政区的ICC和ECC官方死亡证明数据和人口估计数。计算年龄标准化死亡率。进行联结点回归分析。结果:在大多数国家,包括美国、英国和澳大利亚,男性和女性的ICC死亡率都有所上升;在包括意大利和法国在内的一些国家,最近几年的增长趋势趋于平稳。在男性中,2016年左右,香港特别行政区、葡萄牙、法国、西班牙、澳大利亚、奥地利、英国和加拿大的发病率最高(1.7-2.3/10万);拉丁美洲国家和一些东欧国家的发病率最低(0.2-0.8/10万)。在女性中观察到类似的模式,但发病率较低(从香港特别行政区的1.7/10万到阿根廷的0.14/10万)。ECC死亡率在大多数欧洲和澳大拉西亚国家下降,但在美洲有上升趋势。2016年左右,男女比例都低于1/10万,唯一的例外是日本(2.6/10万男性和1.2/10万女性)和匈牙利(1.5/10万男性和1.1/10万女性)。结论:在世界大多数地区,ICC死亡率增加,可能是由于危险因素的增加和癌症识别和分类的改进。大多数国家的ECC死亡率下降,主要是由于胆囊切除术的广泛使用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Multidisciplinary assessment of tumor response after internal and external radiation therapy for hepatocellular carcinoma Interpretation of the updates of the chinese guidelines for the diagnosis and treatment of primary liver cancer (CNLC-2024 Edition) Hepatic arterial infusion chemotherapy: a review with technical notes Measures for response assessment in HCC treatment Impact of diet and gut microbiota changes in the development of hepatocellular carcinoma
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1